UroGen Pharma Ltd. (URGN)
| Market Cap | 1.68B |
| Revenue (ttm) | 140.49M |
| Net Income (ttm) | -133.23M |
| Shares Out | 48.72M |
| EPS (ttm) | -2.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,348,411 |
| Open | 34.29 |
| Previous Close | 34.38 |
| Day's Range | 33.73 - 35.10 |
| 52-Week Range | 12.73 - 36.08 |
| Beta | 1.62 |
| Analysts | Strong Buy |
| Price Target | 36.88 (+6.78%) |
| Earnings Date | Aug 6, 2026 |
About URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocal... [Read more]
Financial Performance
In 2025, UroGen Pharma's revenue was $109.79 million, an increase of 21.45% compared to the previous year's $90.40 million. Losses were -$153.49 million, 21.0% more than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for URGN stock is "Strong Buy." The 12-month stock price target is $36.88, which is an increase of 6.78% from the latest price.
News
UroGen Pharma Transcript: AGM 2026
The meeting reviewed strong product launches and pipeline progress, approved all board proposals, and confirmed a quorum with 75.7% of shares represented. No shareholder questions were submitted, and all proposals passed with final results to be filed within four business days.
UroGen Pharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
ZUSDURI is driving strong growth due to ease of use, robust data, and expanding adoption in community practices. UGN-103 is set for FDA filing in Q3 2024, with approval and market transition expected by 2028. The pipeline includes a phase I oncolytic virus program and plans for broader indications.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
Agreement reinforces the value of UroGen's innovation and reflects the strength of the Company's intellectual property portfolio Teva will be granted a non-exclusive license to sell its generic versio...
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced...
UroGen Pharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
ZUSDURI continues to gain traction as a primary therapy for recurrent low-grade intermediate-risk bladder cancer, with strong Q1 revenue growth and increasing physician adoption. The pipeline advances with UGN-103 on track for a 2027 approval and UGN-501 entering phase I trials this year.
UroGen Pharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The discussion highlighted the proprietary RTGel platform, strong clinical durability for ZUSDURI, and a large market opportunity in NMIBC. Commercial momentum is robust, with revenue growth and expanding community adoption, while successor products and IP strategy aim to extend exclusivity to 2042.
UroGen Pharma reports month results from UTOPIA trial
UroGen Pharma (URGN) announced UGN-103 achieved a 94.5% durability of response at six months by Kaplan-Meier estimate, in the ongoing Phase 3 UTOPIA trial of UGN-103 for intravesical solution in…
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma Transcript: Bank of America Global Healthcare Conference 2026
ZUSDURI's rapid adoption and strong Q1 revenue were driven by improved reimbursement and positive physician experiences, with durable efficacy shown in long-term trial data. Pipeline assets like UGN-103 and UGN-501 are advancing, and upcoming conference events will highlight new clinical results.
UroGen Pharma presents 36-month ENVISION trial data
UroGen Pharma (URGN) announced a 36-month duration of response of 64.5% by Kaplan-Meier estimate in patients who achieved a complete response at three months in the pivotal Phase 3 ENVISION…
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three Months First and Only FDA-Approved Medicine for Recurrent Low-Grade Interme...
UroGen Pharma assumed with a Buy at Ladenburg
Ladenburg assumed coverage of UroGen Pharma (URGN) with a Buy rating and $43 price target The firm says the strong early commercial adoption of Zusduri provides a “significantly de-risking path…
UroGen Pharma price target raised to $45 from $40 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on UroGen Pharma (URGN) to $45 from $40 and keeps a Buy rating on the shares. The firm views the…
UroGen Pharma price target raised to $40 from $34 at Oppenheimer
Oppenheimer raised the firm’s price target on UroGen Pharma (URGN) to $40 from $34 and keeps an Outperform rating on the shares. Zusduri’s Q1 sales of $29.2M vs. the firm/consensus…
UroGen Pharma to Present at Upcoming Investor Conferences
PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma reports Q1 EPS (47c), consensus (36c)
Reports Q1 revenue $50.96M, consensus $55.71M. “2026 is off to a strong start, with expanding usage of ZUSDURI for intravesical solution and clear acceleration across key commercial indicators, includ...
UroGen Pharma Earnings Call Transcript: Q1 2026
Q1 2026 revenue surged 152% year-over-year to $51 million, led by ZUSDURI's rapid launch and strong prescriber growth. JELMYTO maintained stable demand, and the company expects continued ZUSDURI expansion, especially in community practices, with a solid cash position supporting ongoing growth.
UroGen Pharma Earnings release: Q1 2026
UroGen Pharma released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
UroGen Pharma Quarterly report: Q1 2026
UroGen Pharma has published its Q1 2026 quarterly earnings report on May 6, 2026.
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026 JELMYTO achiev...
UroGen Pharma Proxy statement: Proxy filing
UroGen Pharma filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET
UroGen Pharma Proxy statement: Proxy filing
UroGen Pharma filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
UroGen Pharma initiated with a Buy at Jefferies
Jefferies analyst Amin Makarem initiated coverage of UroGen Pharma (URGN) with a Buy rating and $40 price target The firm says the company’s Zusduri has “strong” Phase 3 efficacy and…